Similarly, LSD1 inhibitors can resensitize CRPC to AR blockade, but in lung adenocarcinoma, LSD1 inhibition disrupts EGFR and KRAS pathways with variable effects on tumor growth (79, 114). This evidence concerns the gene AR and neoplasm.